Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used as molecularly targeted drugs for non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations1–3. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.